Oral Drug Delivery Market - Global Industry Analysis

Market Overview

The Global Oral Drug Delivery Market accounted for USD 119.92 Billion in 2020 and is expected to reach USD 220.32 Billion by 2028, growing at a CAGR of 7.9% from 2021 to 2028.

Oral Drug Delivery is the most conducive and favored route of drug administration due to the factors such as least sterility constraints, patient compliance, flexibility in the design of dosage form, ease of production and cost effectiveness. The oral route of drug administration has developed over last few years, with the help of technologies and clinical trials. The market is primarily driven by increase in the prevalence of chronic diseases leading to increase in the demand for oral drug delivery systems for the treatment of such chronic diseases. To maintain the efficiency of oral drug delivery, there has been utilization of nanocarriers for oral drug delivery. The recent developments such as dome tablets, intestinal patches, polymer nano systems, dual drug tablets have been revolutionizing the field.

COVID-19 Impact Analysis

The COVID-19 pandemic has brought some serious medical, social and economic challenges. The supply chain eco-system has been disrupted which has led to the shortage of production. The restricted lockdowns and closed international borders have led to barriers in the transportation which has eventually led to the shortage of the raw materials. Also, the social distancing norms has led to the number of employees working in the industry for production, thus affecting the production of oral drugs.

Growth Factors

The rising prevalence of the chronic diseases has been driving the oral drug delivery market. The growth in the research and development by various pharmaceutical companies has boosted the market. Among the drug delivery routes, oral drug delivery is most preferred one in various therapeutic areas which is also the reason to boost this market.

The growth in the biologics market and the increasing penetration of health insurance will boost the market growth. Also, increasing number of pharmaceutical companies have been driving the market. The technological developments and the new product launches in the market has also accelerated the overall drug delivery market.

Report Scope :

Type Analysis Preview

This is due to the fact that controlled drug delivery has advantages such as the total dose is low, it has reduced dosing frequency, is better accepted by patients and is more complaint, has more uniform drug effect and has improved efficacy/safety ratio. It is the method which delivers the drug at a predetermined rate, systematically or locally, for a specified period of time.

End Users Analysis Preview

The is mainly due to the reasons such as huge number of inpatient and outpatient visits to hospitals coming for the treatments. The high number of inpatient and outpatient visiting the hospitals increases the requirement of huge number of drugs to be administered to the patients in the hospitals. Therefore, hospitals form the major segment in the end users of oral drug delivery systems.

These centers are 45-60% less expensive than the hospitals, thus provide a significant saving to the patients. Also, the outcomes found are more improved ones and infection rates are less as compared to hospitals. The Ambulatory Surgical Centers have their services operating 24/7 and can handle any type of illness, surgery or emergency.

Product Analysis Preview

This is due to the factors such as new production techniques introduced to produce the syrups, available in variety of composition for the consumers and increased effectives to treat the infections and diseases. The content of the syrups provides useful vitamins, rich minerals and proteins required for the overall development of the patients. Thus, the health benefits and the wide availability is driving this segment in the Oral drug delivery market.

Regional Analysis Preview

North America held a share of 39% in 2020. This is due to the factors such as presence of large number of pharmaceutical companies, robust pharmaceutical industry, drug delivery technology providers and rising number of collaborations between technology providers and pharmaceutical companies. Also, the increased demand for self-administration and home healthcare devices, transdermal patches and transmucosal systems for chronic diseases and increasing applications of inhalers have boosted the market in this region.

Asia-Pacific is expected to have the CAGR of 9.3% from 2021 to 2028. This is due to the factors such as saturation of the western markets and economic downfall in US and Europe. In addition, the factors such as rise in the disposable incomes, increasing penetration of the health insurance, development of healthcare infrastructure and increasing chronic diseases are boosting the overall market in this region.   

Key Market Players & Competitive Landscape

Some of the key players in the Oral Drug Delivery market include AdhexPharma, Protalix, CURE Pharamceutical, Evonik, Arx LLC, Catalent Inc., INTELGENX CORP, Assembly Biosciences Inc., Aquestive Therapeutics, Emisphere Technologies, ZIM Laboratories Limited, Adare Pharmaceuticals, Merrion Pharmaceuticals Plc, Oramed Pharmaceuticals, Samyang Corporation, Chimerix Inc., Skypepharma, Amcor Limited and Unigene Laboratories Inc. amog others.

In 2020, Novo Nordisk acquired Emisphere, a drug delivery company, on a cash-free, debt free basis, for $1.35 billion. With the acquisition Novo Nordisk obtained full access to the Eligen  SNAC technology platform thereby expanding its portfolio of oral biologic pipeline assets across therapy areas.

The Global Oral Drug Delivery Market is segmented as follows:

By Type

• Controlled Release
• Orodispersible Tablets

By End Users

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers

By Product

• Tablets
• Syrups

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

• Chapter No. 1 Introduction
  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. USP & Key Offerings
  • 1.2. Key Benefits for Stakehulders
  • 1.3. Target Audience
  • 1.4. Report Scope
• Chapter No. 2 Executive Summary
  • 2.1. Key Findings
    • 2.1.1. Top Investment Pockets
      • 2.1.1.1. Market Attractiveness Analysis, By Type
      • 2.1.1.2. Market Attractiveness Analysis, By End Users
      • 2.1.1.3. Market Attractiveness Analysis, By Product
      • 2.1.1.4. Market Attractiveness Analysis, By Region
  • 2.2. Market Snapshot
  • 2.3. Global Oral Drug Delivery Market, 2016 – 2028 (USD Million)
  • 2.4. Insights from Primary Respondents
• Chapter No. 3 COVID 19 Impact Analysis
  • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. The Middle-East and Africa
  • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
  • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
  • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
  • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
    • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
  • 3.6. Short Term Dynamics
  • 3.7. Long Term Dynamics
• Chapter No. 4 Oral Drug Delivery Market – Type Segment Analysis
  • 4.1. Overview
    • 4.1.1. Market Revenue Share, By Type , 2020 & 2028
  • 4.2. Contrulled Release
    • 4.2.1. Market Size and Forecast, By Region (USD Million)
    • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.3. Orodispersible Tablets
    • 4.3.1. Market Size and Forecast, By Region (USD Million)
    • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
• Chapter No. 5 Oral Drug Delivery Market – End Users Segment Analysis
  • 5.1. Overview
    • 5.1.1. Market Revenue Share, By End Users , 2020 & 2028
  • 5.2. Hospitals
    • 5.2.1. Market Size and Forecast, By Region (USD Million)
    • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 5.3. Diagnostic Centers
    • 5.3.1. Market Size and Forecast, By Region (USD Million)
    • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • 5.4. Ambulatory Surgical Centers
    • 5.4.1. Market Size and Forecast, By Region (USD Million)
    • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
• Chapter No. 6 Oral Drug Delivery Market – Product Segment Analysis
  • 6.1. Overview
    • 6.1.1. Market Revenue Share, By Product , 2020 & 2028
  • 6.2. tablets
    • 6.2.1. Market Size and Forecast, By Region (USD Million)
    • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 6.3. syrups
    • 6.3.1. Market Size and Forecast, By Region (USD Million)
    • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
• Chapter No. 7 Oral Drug Delivery Market – Regional Analysis
  • 7.1. Overview
    • 7.1.1. Global Market Revenue Share, By Region, 2020 & 2028
    • 7.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.2.2. North America Market Revenue, By Type , 2016 – 2028
    • 7.2.3. North America Market Revenue, By End Users , 2016 – 2028
    • 7.2.4. North America Market Revenue, By Product , 2016 – 2028
    • 7.2.5. U.S.
      • 7.2.5.1. U.S. Market Revenue, By Type , 2016 – 2028
      • 7.2.5.2. U.S. Market Revenue, By End Users , 2016 – 2028
      • 7.2.5.3. U.S. Market Revenue, By Product , 2016 – 2028
    • 7.2.6. Canada
      • 7.2.6.1. Canada Market Revenue, By Type , 2016 – 2028
      • 7.2.6.2. Canada Market Revenue, By End Users , 2016 – 2028
      • 7.2.6.3. Canada Market Revenue, By Product , 2016 – 2028
    • 7.2.7. Mexico
      • 7.2.7.1. Mexico Market Revenue, By Type , 2016 – 2028
      • 7.2.7.2. Mexico Market Revenue, By End Users , 2016 – 2028
      • 7.2.7.3. Mexico Market Revenue, By Product , 2016 – 2028
  • 7.3. Europe
    • 7.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.3.2. Europe Market Revenue, By Type , 2016 – 2028
    • 7.3.3. Europe Market Revenue, By End Users , 2016 – 2028
    • 7.3.4. Europe Market Revenue, By Product , 2016 – 2028
    • 7.3.5. Germany
      • 7.3.5.1. Germany Market Revenue, By Type , 2016 – 2028
      • 7.3.5.2. Germany Market Revenue, By End Users , 2016 – 2028
      • 7.3.5.3. Germany Market Revenue, By Product , 2016 – 2028
    • 7.3.6. France
      • 7.3.6.1. France Market Revenue, By Type , 2016 – 2028
      • 7.3.6.2. France Market Revenue, By End Users , 2016 – 2028
      • 7.3.6.3. France Market Revenue, By Product , 2016 – 2028
    • 7.3.7. U.K.
      • 7.3.7.1. U.K. Market Revenue, By Type , 2016 – 2028
      • 7.3.7.2. U.K. Market Revenue, By End Users , 2016 – 2028
      • 7.3.7.3. U.K. Market Revenue, By Product , 2016 – 2028
    • 7.3.8. Italy
      • 7.3.8.1. Italy Market Revenue, By Type , 2016 – 2028
      • 7.3.8.2. Italy Market Revenue, By End Users , 2016 – 2028
      • 7.3.8.3. Italy Market Revenue, By Product , 2016 – 2028
    • 7.3.9. Spain
      • 7.3.9.1. Spain Market Revenue, By Type , 2016 – 2028
      • 7.3.9.2. Spain Market Revenue, By End Users , 2016 – 2028
      • 7.3.9.3. Spain Market Revenue, By Product , 2016 – 2028
    • 7.3.10. Rest of Europe
      • 7.3.10.1. Rest of Europe Market Revenue, By Type , 2016 – 2028
      • 7.3.10.2. Rest of Europe Market Revenue, By End Users , 2016 – 2028
      • 7.3.10.3. Rest of Europe Market Revenue, By Product , 2016 – 2028
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.4.2. Asia Pacific Market Revenue, By Type , 2016 – 2028
    • 7.4.3. Asia Pacific Market Revenue, By End Users , 2016 – 2028
    • 7.4.4. Asia Pacific Market Revenue, By Product , 2016 – 2028
    • 7.4.5. China
      • 7.4.5.1. China Market Revenue, By Type , 2016 – 2028
      • 7.4.5.2. China Market Revenue, By End Users , 2016 – 2028
      • 7.4.5.3. China Market Revenue, By Product , 2016 – 2028
    • 7.4.6. Japan
      • 7.4.6.1. Japan Market Revenue, By Type , 2016 – 2028
      • 7.4.6.2. Japan Market Revenue, By End Users , 2016 – 2028
      • 7.4.6.3. Japan Market Revenue, By Product , 2016 – 2028
    • 7.4.7. India
      • 7.4.7.1. India Market Revenue, By Type , 2016 – 2028
      • 7.4.7.2. India Market Revenue, By End Users , 2016 – 2028
      • 7.4.7.3. India Market Revenue, By Product , 2016 – 2028
    • 7.4.8. South Korea
      • 7.4.8.1. South Korea Market Revenue, By Type , 2016 – 2028
      • 7.4.8.2. South Korea Market Revenue, By End Users , 2016 – 2028
      • 7.4.8.3. South Korea Market Revenue, By Product , 2016 – 2028
    • 7.4.9. South-East Asia
      • 7.4.9.1. South-East Asia Market Revenue, By Type , 2016 – 2028
      • 7.4.9.2. South-East Asia Market Revenue, By End Users , 2016 – 2028
      • 7.4.9.3. South-East Asia Market Revenue, By Product , 2016 – 2028
    • 7.4.10. Rest of Asia Pacific
      • 7.4.10.1. Rest of Asia Pacific Market Revenue, By Type , 2016 – 2028
      • 7.4.10.2. Rest of Asia Pacific Market Revenue, By End Users , 2016 – 2028
      • 7.4.10.3. Rest of Asia Pacific Market Revenue, By Product , 2016 – 2028
  • 7.5. Latin America
    • 7.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.5.2. Latin America Market Revenue, By Type , 2016 – 2028
    • 7.5.3. Latin America Market Revenue, By End Users , 2016 – 2028
    • 7.5.4. Latin America Market Revenue, By Product , 2016 – 2028
    • 7.5.5. Brazil
      • 7.5.5.1. Brazil Market Revenue, By Type , 2016 – 2028
      • 7.5.5.2. Brazil Market Revenue, By End Users , 2016 – 2028
      • 7.5.5.3. Brazil Market Revenue, By Product , 2016 – 2028
    • 7.5.6. Argentina
      • 7.5.6.1. Argentina Market Revenue, By Type , 2016 – 2028
      • 7.5.6.2. Argentina Market Revenue, By End Users , 2016 – 2028
      • 7.5.6.3. Argentina Market Revenue, By Product , 2016 – 2028
    • 7.5.7. Rest of Latin America
      • 7.5.7.1. Rest of Latin America Market Revenue, By Type , 2016 – 2028
      • 7.5.7.2. Rest of Latin America Market Revenue, By End Users , 2016 – 2028
      • 7.5.7.3. Rest of Latin America Market Revenue, By Product , 2016 – 2028
  • 7.6. The Middle-East and Africa
    • 7.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.6.2. The Middle-East and Africa Market Revenue, By Type , 2016 – 2028
    • 7.6.3. The Middle-East and Africa Market Revenue, By End Users , 2016 – 2028
    • 7.6.4. The Middle-East and Africa Market Revenue, By Product , 2016 – 2028
    • 7.6.5. GCC Countries
      • 7.6.5.1. GCC Countries Market Revenue, By Type , 2016 – 2028
      • 7.6.5.2. GCC Countries Market Revenue, By End Users , 2016 – 2028
      • 7.6.5.3. GCC Countries Market Revenue, By Product , 2016 – 2028
    • 7.6.6. South Africa
      • 7.6.6.1. South Africa Market Revenue, By Type , 2016 – 2028
      • 7.6.6.2. South Africa Market Revenue, By End Users , 2016 – 2028
      • 7.6.6.3. South Africa Market Revenue, By Product , 2016 – 2028
    • 7.6.7. Rest of Middle-East Africa
      • 7.6.7.1. Rest of Middle-East Africa Market Revenue, By Type , 2016 – 2028
      • 7.6.7.2. Rest of Middle-East Africa Market Revenue, By End Users , 2016 – 2028
      • 7.6.7.3. Rest of Middle-East Africa Market Revenue, By Product , 2016 – 2028
• Chapter No. 8 Oral Drug Delivery Market – Industry Analysis
  • 8.1. Introduction
  • 8.2. Market Drivers
    • 8.2.1. Driving Factor 1 Analysis
    • 8.2.2. Driving Factor 2 Analysis
  • 8.3. Market Restraints
    • 8.3.1. Restraining Factor Analysis
  • 8.4. Market Opportunities
    • 8.4.1. Market Opportunity Analysis
  • 8.5. Porter’s Five Forces Analysis
  • 8.6. PEST Analysis
  • 8.7. Regulatory Landscape
  • 8.8. Technulogy Landscape
  • 8.9. Regional Market Trends
    • 8.9.1. North America
    • 8.9.2. Europe
    • 8.9.3. Asia Pacific
    • 8.9.4. Latin America
    • 8.9.5. The Middle-East and Africa
  • 8.10. Pricing Analysis
  • 8.11. Value Chain Analysis
  • 8.12. Downstream Buyers
  • 8.13. Distributors/Traders List
• Chapter No. 9 Competitive Landscape
  • 9.1. Company Market Share Analysis – 2019
    • 9.1.1. Global Oral Drug Delivery Market: Company Market Share, 2019
    • 9.1.2. Global Oral Drug Delivery Market, Company Market Revenue, 2016 – 2019 (USD Million)
    • 9.1.3. Global Oral Drug Delivery Market, Company Y-o-Y Growth, 2017 – 2019 (%)
    • 9.1.4. Global Oral Drug Delivery Market: Radar Determinant Chart, 2019
  • 9.2. Strategic Developments
    • 9.2.1. Acquisitions & Mergers
    • 9.2.2. New Product Launch
    • 9.2.3. Regional Expansion
  • 9.3. Company Strategic Developments – Heat Map Analysis
• Chapter No. 10 Company Profiles
  • 10.1. AdhexPharma
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Product Portfulio
    • 10.1.4. Financial Overview
    • 10.1.5. Operating Business Segments
    • 10.1.6. Business Performance
    • 10.1.7. Recent Developments
  • 10.2. Protalix
  • 10.3. CURE Pharamceutical
  • 10.4. Evonik
  • 10.5. Arx LLC
  • 10.6. Catalent Inc.
  • 10.7. INTELGENX CORP
  • 10.8. Assembly Biosciences Inc.
  • 10.9. Aquestive Therapeutics
  • 10.10. Emisphere Technulogies
  • 10.11. ZIM Laboratories Limited
  • 10.12. Adare Pharmaceuticals
  • 10.13. Merrion Pharmaceuticals Plc
  • 10.14. Oramed Pharmaceuticals
  • 10.15. Samyang Corporation
  • 10.16. Chimerix Inc.
  • 10.17. Skypepharma
  • 10.18. Amcor Limited
  • 10.19. Unigene Laboratories Inc.
• Chapter No. 11 Marketing Strategy Analysis
  • 11.1. Marketing Channel
  • 11.2. Direct Marketing
  • 11.3. Indirect Marketing
  • 11.4. Marketing Channel Development Trends
  • 11.5. Economic/Pulitical Environmental Change
• Chapter No. 12 Research Methodulogy
  • 12.1. Research Methodulogy
  • 12.2. Phase I - Secondary Research
  • 12.3. Phase II - Data Modeling
    • 12.3.1. Company Share Analysis Model
    • 12.3.2. Revenue Based Modeling
  • 12.4. Phase III - Primary Research
  • 12.5. Research Limitations
    • 12.5.1. Assumptions